Purpose of review Nonalcoholic steatohepatitis (NASH) is projected to become the most common indication for liver transplantation in the near future. NASH recipients have concurrent obesity, metabolic, and cardiovascular risks, which directly impact patient selection, posttransplant morbidity and potentially long-term outcomes. The purpose of this review is to highlight strategies to optimize pretransplant selection, outcomes, and posttransplant risk modification to optimize patient and graft survival.
INTRODUCTION
Nonalcoholic steatohepatitis (NASH) is an increasing indication for liver transplantation [1] and is projected to become the most frequent indication in the coming decades [2 & ]. NASH is associated with metabolic syndrome and other comorbidities that may impact liver transplant candidacy and posttransplant outcomes. At this time based on large database reviews, patients with NASH can anticipate similar graft and patient survival as other transplant recipients [1, 3] . This review will address preliver transplantation issues specific to NASH as well as review the risk for recurrent disease and comorbidities on the long term outcome of the NASH recipient.
PRETRANSPLANT CONSIDERATIONS IN NASH RECIPIENTS
The selection process for liver transplantation candidates is based on two important criteria ability to withstand the complex surgery without major subsequent morbidity and benefit from liver transplantation. Age, severity of liver disease, coronary artery disease (CAD), diabetes mellitus, obesity, and renal failure are individual risk predictors of poor postoperative and late outcomes. Among liver transplant candidates, patients with NASH represent a particularly challenging group because they are most likely to have these risk factors, which may contribute in both an independent and additive
Cardiovascular risk assessment
Multiple studies have demonstrated that nonalcoholic fatty liver disease (NAFLD) is associated with increased risk for cardiovascular events [4] [5] [6] [7] [8] . NAFLD has been associated with increased intimamedia thickness and plaque [4] , arterial stiffness [5] , coronary artery calcifications [6] , CAD [9] , subclinical myocardial remodeling, ventricular dysfunction [10] , risk of atrial fibrillation [7] , and heart valve calcifications [8] . Whether the increased cardiovascular risk is directly attributed to NAFLD traits (such as simple steatosis, hepatic inflammation, or increased oxidative stress) independent of the coexisting dysmetabolic traits of obesity (such as insulin resistance, visceral adiposity, and atherogenic dyslipidemia) remains to be elucidated. What remains clear is that, compared to other cirrhotics, NASH cirrhosis confers a higher risk of cardiovascular events after liver transplantation, more commonly in the early postoperative period [11] . The most common cardiovascular events include acute pulmonary edema (18%), new onset atrial fibrillation (10%) and sudden cardiac arrest (8%) [11] . The proatherogenic environment of NAFLD and obesity comes in addition to the predisposition to cirrhotic cardiomyopathy, which is present in up to 50% of cirrhotics, independent of liver disease cause [12] .
These findings highlight the need for careful selection of the NASH liver transplantation candidate; the general approach followed at our institution is depicted in Fig. 1 . However, there are currently no specific guidelines for preoperative assessment in this population. The sensitivity and specificity of noninvasive testing in diagnosing CAD in the general population is summarized in Table 1 [13] . Dobutamine stress echocardiography (DSE) has been advocated as the assessment tool of choice in NASH liver transplantation candidates. The high negative predictive value of DSE, when target heart rates are achieved, allows it to be used to identify a low-risk group. However, several studies have shown that DSE has a poor performance to predict the risk
KEY POINTS
Recurrent and de-novo steatosis are common after liver transplantation, although progressive NASH is less frequent. Moreover, NASH recipients have excellent 5-year patient and graft survival following liver transplantation.
NAFLD traits such as hepatic steatosis, obesity, and the coexisting dysmetabolic traits, such as insulin resistance, visceral adiposity, and atherogenic dyslipidemia impart increased cardiovascular risk to these patients.
Pharmacotherapy for risk factor reduction is recommended in the NASH liver transplantation recipient, specifically targeting cardiovascular risk factors.
Bariatric surgery should be considered early in the NASH recipient, and may even be considered at the time of liver transplantation. 
Weight and BMI as selection criteria
The low number of studies with liver transplantation recipients with class III obesity (BMI >40 kg/m 2 ) would suggest that BMI may play a role in patient selection. Most studies seem to agree that obesity alone does not negatively impact long-term graft and patient survival, though it does impart an increase in early posttransplant morbidity [17, 18] , whereas some have shown that BMI is an independent predictor of death if above 40 kg/m 2 [19, 20] . Additionally, intra-abdominal adiposity poses challenges to the surgical technique, but there are no data on its impact on postoperative complications [21] . Except at the extremes of BMI, obesity alone should not represent a significant contraindication to liver transplantation and should not be considered in isolation as a factor precluding successful transplantation. In fact, these patients may be considered for concurrent bariatric surgery, an approach taken by some transplant centers in recent years. Heimbach et al. [22] reported that sleeve gastrectomy at the time of liver transplant in a carefully selected population of obese liver transplant candidates who failed an aggressive noninvasive weight loss program results in effective and sustained weight loss and no posttransplant metabolic complications (allograft steatosis, diabetes mellitus).
Pretransplant diabetes mellitus
Pretransplant diabetes mellitus in combination with obesity is a strong predictor of early postoperative complications (infections, cardiovascular events) and length of hospital stay compared to obesity alone or with other cardiovascular risk factor [23] . Additionally, pretransplant diabetes mellitus is associated with lower long-term patient and graft survival, with deaths mainly attributed to cardiovascular complications, infections, and renal failure [24] . In a United Network for Organ Sharing (UNOS) database study, patients with preexisting CAD and diabetes mellitus documented at the time of registration on the waiting list were 60% more likely to die after liver transplantation when compared with patients with either disease alone [24] . Therefore, in patients with diabetes mellitus, especially in the presence of diabetes mellitus-related organ damage consistent with micro or macrovascular complications, in particular, renal and cardiovascular function should be carefully assessed, and periodically reassessed if faced with long wait times to organ transplantation.
Other issues
Additional risk factors associated with obesity and NASH, such as chronic kidney disease [25] and obstructive sleep apnea and its cardiopulmonary complications (pulmonary hypertension and right heart failure) should be sought early and optimized. The greatest challenge in the selection of liver transplantation candidates with NASH is how to integrate the multiple risk factors into one accurate risk stratification tool. Until then, sound clinical judgment of the overall metabolic risk profile of a Based on 2013 ESC guidelines on the management of stable coronary artery disease [12] . CT, computed tomography; SPECT, single-photon emission computed tomography.
candidate, instead of independent predictors should be used (Table 2) .
POSTLIVER TRANSPLANTATION NONALCOHOLIC FATTY LIVER DISEASE
Recurrent and de-novo NAFLD are common postliver transplantation; whereas, progressive NASH is less common. The incidence, outcomes, cardiovascular risks, and possible therapies are discussed in this section.
Incidence
Several studies have shown a high incidence of postliver transplantation NAFLD in patients transplanted for NASH or cryptogenic cirrhosis [26] [27] [28] [29] [30] [31] [32] ( Table 3) . This is significantly greater than the prevalence of NAFLD in patients transplanted for indications other than NASH or cryptogenic cirrhosis, 25%
in patients followed 5-year postliver transplantation [26, 30] ; Whereas, in another cohort, de-novo steatosis was reported to occur in 40% of recipients and NASH in 13% of recipients transplanted for chronic hepatitis B or C [31] . The use of corticosteroids for immunosuppression, pretransplant BMI, postliver transplantation BMI, tacrolimus-based immunosuppressive regimen, diabetes mellitus, hyperlipidemia, and arterial hypertension are risk factors for postliver transplantation steatosis [26, 32] , whereas the use of angiotensin converting enzyme inhibitors was associated with a lower steatosis risk [30] . The incidence of NASH reported in various series, which includes both living donor and deceased donor liver transplantation, with patients followed for varying periods of time (28-64 months), ranges from 4% (median interval between transplant and first biopsy was 40 months, range 6-189 months, [32] ) to 14% (median follow-up 64 months, [29] ). However, the risk factors for progressive NASH are less well 
Patient and graft survival
The reported 1-year survival for NASH recipients ranges from 85-90% and 5-year survival ranges from 70-80% (Fig. 2) [1] . The other large, United Network for Organ Sharing database analysis by Afzali et al. included 69 962 patients from 1997 to 2010. Of these NASH was a primary liver transplantation indication in 1810 recipients, and cryptogenic cirrhosis was a primary indication in 3843 recipients. This study showed decreased risk of death and graft failure when adjustments were made for both donor and recipient characteristics [3] , with 87.6% 1-year, 82.2% 3-year, and 75.75% 5year patient survival among NASH recipients. The study by Afzali et al. excluded from the NASH category those recipients that also had a diagnosis of hepatocellular carcinoma. This might account for the better patient survival reported by them. Although both studies overall showed excellent patient and graft survival in those transplanted for NASH as a primary indication, the study by Afzali et al. showed postliver transplant survival among those transplanted for NASH was higher than some patient groups (hepatocellular carcinoma, hepatitis C, alcoholic liver disease, acute hepatic necrosis, hemochromatosis, cryptogenic cirrhosis), though inferior to others (primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, hepatitis B). Thus, in the current era of liver transplantation, NASH imparts equivalent if not superior postliver transplantation patient and graft survival.
Cardiovascular disease in nonalcoholic steatohepatitis recipients
Cardiovascular disease imparts the most significant mortality risk in the NASH patient population, and this is likely true in the posttransplant NASH recipients as well [35,36 & ]. Potential transplant recipients with cardiac risk factors are stringently screened for the presence of atherosclerotic CAD. Furthermore, many risk factors, such as hyperlipidemia, are masked secondary to impaired hepatic synthesis in cirrhosis. Therefore, the increased incidence of cardiovascular disease-related morbidity in NASH liver transplantation recipients [11, 37] compared with both those transplanted for other indications, and population matched controls is a significant problem. Moreover, this may reflect an accelerated disease course in these at-risk patients, who were screened for the absence of significant cardiovascular disease pretransplantation [36 & ,37] . The presence of pretransplant cardiovascular disease, postoperative sepsis, diabetes mellitus, and elevated preliver transplantation serum troponins were predictors of postliver transplantation cardiovascular disease in liver transplant recipients [16, 38, 39] , though these studies did not perform subgroup analyses for NASH recipients. Extrapolating from the pretransplant and general population-based studies, male sex, and age also impart significant risk, though remain unmodifiable. Among the modifiable cardio-metabolic risk factors are smoking, diabetes mellitus, hypertension (preexisting and de novo), hyperlipidemia, postliver transplantation renal insufficiency, and the use of mycophenolate mofetil [36 & ,37]. In the study by Albeldawi et al. [37] which looked at cardiovascular events among all liver transplantation recipients (NASH and others), mycophenolate mofetil use imparted a hazard ratio of 2.3 for the occurrence of a cardiovascular event postliver transplantation, but confirmatory data for its role in cardiovascular disease is needed. All of these risk factors should be aggressively modified and treated. In the study by Fussner et al. [36 & ], tacrolimus-based immunosuppression was associated with a lower risk of cardiovascular disease. This finding will need to be verified in unique cohorts. Patients with preliver transplantation elevated random serum troponins, left ventricular hypertrophy on echocardiography, lower ejection fraction, and prior cardiovascular disease identifies patients who should receive close followup and aggressive risk factor modification therapy.
Pharmacotherapy for nonalcoholic steatohepatitis and metabolic syndrome
There are no specific randomized controlled trials for pharmacotherapy for NASH in the liver transplantation population. Though vitamin E, pioglitazone and obeticholic acid have shown promise in the treatment of NASH in the nontransplant population [40, 41] , none of these agents has received regulatory agency approval for NASH therapy. Similarly, though several agents are available for the pharmacotherapy of obesity, such as orlistat, lorcaserin, liraglutide, buprepione-naltrexone, these agents have not been studied in the organ transplantation population. Metformin, statins, and ursodeoxycholic acid have been examined for use in NASH in the nontransplant population with no clear benefit [42] [43] [44] . Thus, at present effective pharmacotherapy for NASH amelioration, both in the nontransplant and posttransplant population is lacking. However, recognizing the significant risk imparted by cardiovascular disease in NASH patients, approved therapies for aggressive management of hyperlipidemia, diabetes mellitus, hypertension, and smoking cessation should be pursued in the NASH recipient.
Bariatric surgery in nonalcoholic steatohepatitis recipients
Laparoscopic sleeve gastrectomy after solid organ transplantation, including liver transplantation recipients or open sleeve gastrectomy at the time of liver transplantation are gaining traction as safe and effective bariatric procedures in liver transplant recipients [45, 46] . Owing to concerns regarding malabsorption of medications and the inability to access the biliary tree following roux-en-Y procedures, restrictive bariatric procedures have remained more popular in solid organ transplant recipients, though malabsorptive procedures have been reported. A recent review summarized two bariatric surgery case series each, before liver transplantation and during liver transplantation, and seven postliver transplantation case series [47] . Sleeve gastrectomy was the most frequent bariatric procedure, followed by roux-en-Y gastric bypass. Of the included 54 patients, 26 underwent laparoscopic sleeve gastrectomy before transplant and 11 after transplant open sleeve gastrectomy was performed during liver transplantation in seven patients. Percentage excess weight loss ranged from 26% at 3 months in one study to 64.7% in another, although these numbers should be interpreted with caution because of the small numbers of patients included. Patients had comparable degrees of decrease in BMI, or excess body weight loss regardless of the timing of bariatric surgery. Although increase in morbidity (one leak from the gastric staple line and one excess weight loss) in patients with simultaneous transplantation and bariatric surgery has been reported, the posttransplant reduction in onset of diabetes, weight gain, and steatosis has endured to last follow-up (mean follow-up 33 months) in the study by Heimbach et al. [22] . Delayed sleeve gastrectomy, similarly, is associated with increased early postoperative morbidity, such as mesh dehiscence, bile leak and postoperative dysphagia, each occurring in one of nine patients in this case series, however, acceptable long-term outcomes [46] .
Immunosuppression considerations in nonalcoholic steatohepatitis recipients
Calcineurin inhibitor (CNI) therapy and mammalian target of rapamycin (mTOR) inhibitors impart cardiovascular risks; therefore every attempt should be made to maintain patients on the least effective immunosuppressive therapy. Dumortier et al. [32] reported tacrolimus-based immunosuppression as a risk factor for the development of de-novo steatosis in liver transplant recipients. Hypertension and hyperlipidemia are higher with cyclosporine-based immunosuppression than tacrolimus, though the overall incidence of metabolic syndrome and posttransplant diabetes is unaffected by choice of CNI [48] . Use of the mTOR inhibitors (sirolimus and everolimus) leads to hyperlipidemia, which can be managed with pharmacotherapy. This hyperlipidemia does not increase the risk for cardiovascular or cerebrovascular events, as recently demonstrated in a large case series by Weick et al. [49] . A randomized controlled trial of CNI versus everolimus, although primarily done to look at renal function, also showed similar patient and graft outcomes, though the rate of discontinuation of therapy was higher for everolimus [50] . Though ongoing trials are geared toward defining the lowest effective immunosuppressive agents for liver transplant recipients, in our practice, tacrolimus monotherapy is the most widely used, and efforts should be made to reduce dosage to the minimal effective dose. Alternatively, mTOR inhibitors could be considered in patients with metabolic syndrome and multiple cardiovascular risk factors, to minimize the many metabolic side effects associated with CNI use [32, 39] , but careful follow-up of lipid and glucose is still warranted. Prospective data is needed to show true benefit for mTOR inhibitor use over the CNI.
CONCLUSION
With NASH on trajectory to become the most frequent primary indication for liver transplantation in the near future; one provocative question is how might we improve patient survival further? Although, historically, 5-year patient survival has been an accepted metric for posttransplant outcomes, given the slow onset and progression of NASH, we do we need longer term follow-up and outcomes data. Furthermore, aggressive risk factor modification with life style modification and pharmacotherapy for metabolic syndrome and cardiovascular disease or bariatric surgery for obesity is recommended in NASH recipients.
